The judge hearing patent litigationbetween MRI manufacturer Fonar and competitors GE and Hitachihas postponed a trial date for the case. The litigation, in whichFonar is suing GE, Hitachi and two imaging centers for violatingits basic MRI patents, was
The judge hearing patent litigationbetween MRI manufacturer Fonar and competitors GE and Hitachihas postponed a trial date for the case. The litigation, in whichFonar is suing GE, Hitachi and two imaging centers for violatingits basic MRI patents, was scheduled to go to trial Dec. 5 inU.S. District Court for Eastern New York in Hauppauge, NY. Fonaris claiming damages of $362 million from the defendants (SCAN11/23/94).
The judge delayed the start of the trial because the litigantshave not yet agreed on the appointment of an independent expertwho will instruct the judge and jury in the basics of MRI technology,according to Fonar counsel Ronald Schutz of Robins, Kaplan, Millerand Ciresi in Minneapolis. A new date has not been set for thetrial, although Schutz believes it should begin in the next severalmonths.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.